Waters Corporation WAT
433.54
3.24
0.75%
as of 25 Sep
- Market cap
- $42.3B
- P/E
- 108×
Follow WAT
Indexes
indicate stock being part of an index,
Insider Buys
alert about insiders buying in the last 12 month
Waters Corporation (WAT) Free cash flow margin
Waters Corporation's free cash flow margin over the twelve months to 30 June 2026 was 7.89%, down 8.2 percentage points from fiscal 2025 (16.0%). Over the past ten years it has ranged from −28.4% (fiscal 2023) to 26.3% (fiscal 2017); the current reading is higher than 27% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 16.0% | (4.91) |
| FY2024 | 21.0% | 49.37 |
| FY2023 | −28.4% | (42.83) |
| FY2022 | 14.4% | (6.37) |
| FY2021 | 20.8% | (1.95) |
| FY2020 | 22.7% | 2.82 |
| FY2019 | 19.9% | (1.10) |
| FY2018 | 21.0% | (5.28) |
| FY2017 | 26.3% | 0.82 |
| FY2016 | 25.5% | 2.19 |
Against its own ten years
Low −28.4%
High 26.3%
Ten-year median
21.0%
Current reading's percentile
27
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 27.2% |
| MTD Mettler-Toledo International, Inc. compare | 20.9% |
| ILMN Illumina, Inc. compare | 20.7% |
| A Agilent Technologies, Inc. compare | 17.2% |
| IQV IQVIA Holdings Inc. compare | 13.3% |
| DGX Quest Diagnostics Incorporated compare | 11.7% |
| WAT Waters Corporation | 7.89% |
| NTRA Natera, Inc. compare | 3.11% |
| GH Guardant Health, Inc. compare | −20.4% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on WAT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement